354 related articles for article (PubMed ID: 30455436)
21. Waldenstrom macroglobulinemia cells devoid of BTK
Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
[TBL] [Abstract][Full Text] [Related]
22. Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.
Davis JE; Handunnetti SM; Ludford-Menting M; Sharpe C; Blombery P; Anderson MA; Roberts AW; Seymour JF; Tam CS; Ritchie DS; Koldej RM
Blood Adv; 2020 Oct; 4(19):4849-4859. PubMed ID: 33031542
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Eyre TA; Walter HS; Iyengar S; Follows G; Cross M; Fox CP; Hodson A; Coats J; Narat S; Morley N; Dyer MJS; Collins GP
Haematologica; 2019 Feb; 104(2):e68-e71. PubMed ID: 30190341
[No Abstract] [Full Text] [Related]
24. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Zhao X; Wang MY; Jiang H; Lwin T; Park PM; Gao J; Meads MB; Ren Y; Li T; Sun J; Fahmi NA; Singh S; Sehgal L; Wang X; Silva AS; Sotomayor EM; Shain KH; Cleveland JL; Wang M; Zhang W; Qi J; Shah BD; Tao J
Cell Rep; 2021 Mar; 34(11):108870. PubMed ID: 33730585
[TBL] [Abstract][Full Text] [Related]
26. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma.
Grieve C; Joseph A; Drullinsky P; Zelenetz AD; Hamlin P; Kumar A
Leuk Lymphoma; 2024 Feb; 65(2):235-241. PubMed ID: 38264906
[TBL] [Abstract][Full Text] [Related]
28. Genomics of Resistance to Targeted Therapies.
Thangavadivel S; Woyach JA
Hematol Oncol Clin North Am; 2021 Aug; 35(4):715-724. PubMed ID: 34174982
[TBL] [Abstract][Full Text] [Related]
29. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
[TBL] [Abstract][Full Text] [Related]
30. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Rule S; Dreyling M; Goy A; Hess G; Auer R; Kahl B; Cavazos N; Liu B; Yang S; Clow F; Goldberg JD; Beaupre D; Vermeulen J; Wildgust M; Wang M
Br J Haematol; 2017 Nov; 179(3):430-438. PubMed ID: 28832957
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Cancer Med; 2019 Nov; 8(16):6860-6870. PubMed ID: 31560165
[TBL] [Abstract][Full Text] [Related]
32. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
33. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.
Wang X; Sansam CG; Thom CS; Metzger D; Evans JA; Nguyen PT; Roberts CW
Cancer Res; 2009 Oct; 69(20):8094-101. PubMed ID: 19789351
[TBL] [Abstract][Full Text] [Related]
34. Functional selectivity of recombinant mammalian SWI/SNF subunits.
Kadam S; McAlpine GS; Phelan ML; Kingston RE; Jones KA; Emerson BM
Genes Dev; 2000 Oct; 14(19):2441-51. PubMed ID: 11018012
[TBL] [Abstract][Full Text] [Related]
35. MITF-independent pro-survival role of BRG1-containing SWI/SNF complex in melanoma cells.
Ondrušová L; Vachtenheim J; Réda J; Záková P; Benková K
PLoS One; 2013; 8(1):e54110. PubMed ID: 23349796
[TBL] [Abstract][Full Text] [Related]
36. The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.
Pottier N; Yang W; Assem M; Panetta JC; Pei D; Paugh SW; Cheng C; Den Boer ML; Relling MV; Pieters R; Evans WE; Cheok MH
J Natl Cancer Inst; 2008 Dec; 100(24):1792-803. PubMed ID: 19066270
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional activation by pRB and its coordination with SWI/SNF recruitment.
Flowers S; Beck GR; Moran E
Cancer Res; 2010 Nov; 70(21):8282-7. PubMed ID: 20851996
[TBL] [Abstract][Full Text] [Related]
38. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
39. Cdx2 Regulates Gene Expression through Recruitment of Brg1-associated Switch-Sucrose Non-fermentable (SWI-SNF) Chromatin Remodeling Activity.
Nguyen TT; Savory JGA; Brooke-Bisschop T; Ringuette R; Foley T; Hess BL; Mulatz KJ; Trinkle-Mulcahy L; Lohnes D
J Biol Chem; 2017 Feb; 292(8):3389-3399. PubMed ID: 28082674
[TBL] [Abstract][Full Text] [Related]
40. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
